192 related articles for article (PubMed ID: 32684865)
1. Salvage I-125 brachytherapy for locally-recurrent prostate cancer after radiotherapy.
Pons-Llanas O; Burgos-Burgos J; Roldan-Ortega S; Conde-Moreno A; Celada-Alvarez F; Ruiz-Martinez JC; Lliso-Valverde F; Tormo-Micó A; Perez-Calatayud J; López-Torrecilla J
Rep Pract Oncol Radiother; 2020; 25(5):754-759. PubMed ID: 32684865
[TBL] [Abstract][Full Text] [Related]
2. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
[TBL] [Abstract][Full Text] [Related]
3. Reirradiation salvage radiotherapy for recurrent prostate cancer after primary low-dose brachytherapy.
Muñoz Muñoz Ó; Gomis Sellés E; Delgado León BD; Mateos Perez JC; Baeza Trujillo M; Perucha Ortega M; López Guerra JL; Cabrera Roldán P
Clin Transl Oncol; 2024 Apr; 26(4):872-879. PubMed ID: 37672205
[TBL] [Abstract][Full Text] [Related]
4. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
[TBL] [Abstract][Full Text] [Related]
5. Salvage low-dose-rate (125)I partial prostate brachytherapy after dose-escalated external beam radiotherapy.
Chang L; Buyyounouski MK
J Contemp Brachytherapy; 2014 Oct; 6(3):304-10. PubMed ID: 25337135
[TBL] [Abstract][Full Text] [Related]
6. Salvage Low Dose Rate Brachytherapy For Recurrent Prostate Cancer After External Beam Radiotherapy: Results From A Single Institution With Focus On Toxicity And Functional Outcomes.
Barbera F; Triggiani L; Buglione M; Ghirardelli P; Vitali P; Caraffini B; Borghetti P; Greco D; Bardoscia L; Pasinetti N; Costa L; Maddalo M; Ghedi B; La Face B; Magrini SM
Clin Med Insights Oncol; 2017; 11():1179554917738765. PubMed ID: 29151782
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
Hsu CC; Hsu H; Pickett B; Crehange G; Hsu IC; Dea R; Weinberg V; Gottschalk AR; Kurhanewicz J; Shinohara K; Roach M
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):370-7. PubMed ID: 22672747
[TBL] [Abstract][Full Text] [Related]
8. Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity.
Henríquez I; Sancho G; Hervás A; Guix B; Pera J; Gutierrez C; Abuchaibe O; Martínez-Monge R; Tormo A; Polo A
Radiat Oncol; 2014 Apr; 9():102. PubMed ID: 24885287
[TBL] [Abstract][Full Text] [Related]
9. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control.
Mayrata E; Espinosa JM; Büchser D; Casquero F; Suárez F; González A; Minguez P; Pérez JF; Miguel IS; Cacicedo J; Gómez-Iturriaga A
J Contemp Brachytherapy; 2021 Feb; 13(1):12-17. PubMed ID: 34025731
[TBL] [Abstract][Full Text] [Related]
10. Whole-gland salvage treatment for recurrent prostate cancer after initial definitive radiotherapy: A case series of
Sutani S; Yorozu A; Toya K; Nishiyama T; Ozu C; Yagi Y; Nakamura K; Saito S
J Contemp Brachytherapy; 2019 Jun; 11(3):201-206. PubMed ID: 31435426
[TBL] [Abstract][Full Text] [Related]
11. Protocol-based image-guided salvage brachytherapy. Early results in patients with local failure of prostate cancer after radiation therapy.
Lahmer G; Lotter M; Kreppner S; Fietkau R; Strnad V
Strahlenther Onkol; 2013 Aug; 189(8):668-74. PubMed ID: 23824103
[TBL] [Abstract][Full Text] [Related]
12. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).
Crook JM; Zhang P; Pisansky TM; Trabulsi EJ; Amin MB; Bice W; Morton G; Pervez N; Vigneault E; Catton C; Michalski J; Roach M; Beyer D; Jani A; Horwitz E; Donavanik V; Sandler H
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):335-343. PubMed ID: 30312717
[TBL] [Abstract][Full Text] [Related]
13. A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study.
Miyake M; Tanaka N; Asakawa I; Yamaki K; Inoue T; Suzuki S; Hori S; Nakai Y; Anai S; Torimoto K; Toritsuka M; Nakagawa H; Tsukamoto S; Fujii T; Ohbayashi C; Hasegawa M; Kasahara M; Fujimoto K
Contemp Clin Trials Commun; 2020 Sep; 19():100593. PubMed ID: 32637724
[TBL] [Abstract][Full Text] [Related]
14. Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity.
Rose JN; Crook JM; Pickles T; Keyes M; Morris WJ
Brachytherapy; 2015; 14(3):342-9. PubMed ID: 25727178
[TBL] [Abstract][Full Text] [Related]
15. Salvage Reirradiation Options for Locally Recurrent Prostate Cancer: A Systematic Review.
Zhong J; Slevin F; Scarsbrook AF; Serra M; Choudhury A; Hoskin PJ; Brown S; Henry AM
Front Oncol; 2021; 11():681448. PubMed ID: 34568012
[TBL] [Abstract][Full Text] [Related]
16. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
17. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
18. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
19. A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer.
Ciezki JP; Weller M; Reddy CA; Kittel J; Singh H; Tendulkar R; Stephans KL; Ulchaker J; Angermeier K; Stephenson A; Campbell S; Haber GP; Klein EA
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):962-975. PubMed ID: 28333019
[TBL] [Abstract][Full Text] [Related]
20. Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy failure.
Wojcieszek P; Szlag M; Głowacki G; Cholewka A; Gawkowska-Suwińska M; Kellas-Ślęczka S; Białas B; Fijałkowski M
Radiother Oncol; 2016 Jun; 119(3):405-10. PubMed ID: 27165612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
